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Abstract
An ability to measure cardiac output in a continuous and non-
invasive fashion is eagerly awaited in the field of intensive care
practice. Modern technologies purport to be able to do this, but
the design of studies that validate the manufacturers’ claims is by
no means straightforward. It is imperative that the scientific
community describes and agrees on a set of principles that will
enable us to design and then review and assess future validation
studies, so that new technologies can be fairly assessed and
compared with their competitors.
In recent years there has been a move toward technologies
that monitor cardiac output continuously and in a less
invasive fashion than the pulmonary artery catheter [1-3]. This
has brought many new challenges to the fore that perhaps
had not previously been considered. One of these challenges
pertains to how we validate the accuracy and precision, or in
other words the utility, of the new devices. Difficulty arises
because previous studies assessing intermittent techniques
compared the measurement of cardiac output at a discrete
time point against a reference ‘gold standard’. The statistical
methodologies used to analyze these data are well described
[4,5]. This is not the case for studies assessing continuous
monitoring of cardiac output.
Marque and colleagues [1] present an interesting study that
highlights some of these issues. In their study they demon-
strate that Bioreactance (Cheetah Medical Inc., Tel Aviv,
Israel) can track changes in cardiac output in patients after
cardiac surgery and conclude that its performance is similar
to that of the Vigileo version 1.01 (Edwards Lifesciences,
Irvine, CA, USA). In addition they describe a methodology for
assessing continuous data against a ‘reference’ technique
that tracks the same variable. Bioreactance is a relatively new
method for monitoring cardiac output; it is based on the
principle that the frequency of changes in aortic volume with
the cardiac cycle can be detected by alternating electrical
signals across the thorax. If this were to work then it would be
an almost completely non-invasive method for monitoring
changes in cardiac output.
This statistical analysis deserves some attention. The authors
correctly suggest that it is more important for continuous data
to track changes accurately than it is for them to be precise
measurements of the underlying variable. Indeed, this is how
they are used in clinical practice. It is important to under-
stand, however, that the absolute value must also be valid-
ated; otherwise the tool may be used inappropriately. This
requires intermittent measurements that can be compared
against a recognized reference. In most cases this would be
intermittent thermodilution from the pulmonary artery catheter.
Without this the monitor may be shown to track changes
accurately but may not be a reliable measurement of cardiac
output. For instance if the underlying cardiac output was
5 l/minute and the new monitor described it as 1 l/minute,
then even if it were able to track changes accurately it could
be used inappropriately, with detrimental consequences for
patient management. A relevant analogy for this would be the
validation of altimeters in the aviation industry. For obvious
reasons an altimeter must be able to detect changes in
altitude reliably, but we would be extremely concerned if it
were unable to measure the absolute value accurately!
In their study, Marque and colleagues [1] used two reference
technologies as comparators for Bioreactance. These consist
of continuous cardiac output from the pulmonary artery
catheter (Vigilance; Edwards Lifesciences) and also from
pulse pressure analysis by the Vigileo (software algorithm
version 1.01). Because of the inability of the Vigilance system
to track changes in real time (it calculates time averages over
an approximate 10-minute moving window), the Vigileo was
used as the main reference. This is perhaps unfortunate in
view of the fact that many authors have described limitations
of this software version in monitoring cardiac output; for
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instance, Mayer and coworkers [6] reported percentage
errors up to 46% and de Waal and colleagues [7] up to 33%
in comparison with the pulmonary artery catheter. Newer
versions have been reported to be more accurate and precise
[8,9], but more robust validation data are still awaited. Until
such data become available, the Vigileo remains a strange
choice for a reference tool in a validation study. Despite these
limitations, in their evaluation of Bioreactance Marque and
colleagues [1] describe some exciting results for this new
non-invasive technique. We would advocate caution in
extrapolating these results to clinical practice until they have
been repeated against more reliable references and in other
patient groups. If the technique is proved to work in the
patients in whom it will inevitably be used, then this
technology will be a major advancement in our haemo-
dynamic monitoring abilities.
What becomes abundantly clear from this paper, as well as
many others on a similar subject, is that we have no clear
mechanism for reporting data from validation studies of
continuous measurement techniques. This heterogeneity
limits our ability to generalize data and confuses the readers.
This paper takes us a step forward in interpreting the data,
but there is an urgent need for the scientific community to
come together and develop a consensus on how these
studies should be designed, reported and presented.
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